1. Home
  2. GRND vs MLYS Comparison

GRND vs MLYS Comparison

Compare GRND & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grindr Inc.

GRND

Grindr Inc.

HOLD

Current Price

$12.27

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$28.29

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRND
MLYS
Founded
2009
2019
Country
United States
United States
Employees
148
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.2B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
GRND
MLYS
Price
$12.27
$28.29
Analyst Decision
Buy
Strong Buy
Analyst Count
6
6
Target Price
$19.67
$48.67
AVG Volume (30 Days)
1.2M
1.3M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$23.08
N/A
Revenue Next Year
$17.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.79
$10.44
52 Week High
$25.13
$47.65

Technical Indicators

Market Signals
Indicator
GRND
MLYS
Relative Strength Index (RSI) 53.22 58.05
Support Level $11.83 $26.85
Resistance Level $12.90 $31.09
Average True Range (ATR) 0.46 1.62
MACD -0.07 0.68
Stochastic Oscillator 39.19 87.49

Price Performance

Historical Comparison
GRND
MLYS

About GRND Grindr Inc.

Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: